This study investigated pre-initiation and post-initiation effects of dietary ellagic acid (EA) on 7,12-dimethylbenz[a]anthracene (DMBA) multi-organ carcinogenesis in rainbow trout {Oncorhynchus mykiss). EA at 100, 250 (study 2), 1000 and 2000 (study 1) p.p.m. suppressed stomach adenopapilloma incidence by 33, 60, 70 and 78% (P ^ 0.001), respectively, as well as tumor multiplicity (P < 0.01) and size (P < 0.001) when fed continuously following DMBA initiation. However, continuous EA feeding also produced modest (250 p.p.m.) to extensive (1000, 2000 p.p.m.) growth rate suppression in these studies. Retrospective logistic regression modeling of the data allowed separation of growth-related from non-growth-related inhibitory effects. By this approach: (i) tumor development showed a similarly strong dependence (same regression slope) on animal growth rate in all treatment groups; (ii) EA-mediated reduction in mean population growth contributed to suppressed stomach tumor response above 250 p.p.m. EA; and (iii) even at high, toxic doses EA displayed inhibitory mechanisms additional to, and distinct from, growth suppression effect The effects of post-initiation EA were organ specific Chronic EA treatment significantly suppressed swim-bladder as well as stomach tumor incidence at doses ^ 1000 p.p.m., but increased liver tumor incidence at doses £ 250 p.p.m. Three protocols examined EA effects on the initiation process. EA fed at 1000 p.p.m. concurrently with 750 p.p.m. dietary DMBA for 7 weeks modestly reduced stomach tumor incidence (from 85 to 78%, P < 0.05) and multiplicity (from 63 ± 4.3 to 4.9 ± 2.9, P < 0.01), but did not alter swim-bladder or liver response. The effect of EA pretreatment prior to DMBA single-dose initiation by gill uptake was also examined. When fed for 1 week prior to initiation, 2000 p.p.m. EA again imposed a small reduction in stomach adenoma incidence (from 88 to 78%; P < 0.05) and multiplicity (from 5.5 ± 3.2 to 4.4 ± 3.2; P < 0.01). However, when EA was pre-fed for 3 weeks instead of 1 week, protection in the stomach was lost and response in liver and swimbladder significantly increased. In sum, these studies demonstrate that EA influence on DMBA tumorigenesis in this multi-organ model is highly protocol dependent and organ specific. Post-initiation dietary EA consistently suppressed stomach tumor development in trout, at EA doses far lower than those required for protection in rodents. At higher doses, however, EA also displayed toxicity and a potential in some protocols to enhance tumor response in other organs.
Introduction
Plant-derived polyphenolic compounds are common nonnutrient constituents of the human diet. Ellagitannins are hexahydroxydiphenoyl-based glucose esters that are found mainly in raspberries, strawberries and nuts (1, 2) and which form ellagic acid (EA*) after hydrolysis (3) . Dietary EA has shown anticarcinogenic activity against nitrosamine-induced lung tumors in mice (4) and esophageal tumors in rats (5, 6) . There is evidence that this may reflect inhibition of carcinogen metabolism by EA (7) . EA has also been shown to inhibit polycyclic aromatic hydrocarbon metabolism, DNA binding, and carcinogenicity in rodent models (8) (9) (10) (11) (12) . For example, EA administered topically inhibited benzo[a]pyrene (BaP) skin tumorigenesis in mice (10) , whereas dietary EA blocked BaPinduced lung tumors in mice (11) and 7,12-dimethylbenz[a]anthracene (DMBA) mammary tumors in rats (12) .
Based on its inhibition of carcinogen metabolism and DNA binding, EA can be classified as an anti-initiating, or 'blocking' agent (13) . Relatively little attention has been given to postinitiation effects of this compound, or to its effects in multiorgan models. EA was found to suppress effectively DMBAinitiated, 12-O-tetradecanoyl phorbol-13-acetate (TPA)-promoted mouse skin carcinogenesis (14) . Two recent studies also report suppression of small intestinal tumor development in a multi-organ rat model (15) , and of N-nitrosomethylbenzylamine induced esophageal tumors in the rat (16) . Taken together, these studies indicate that EA may be an effective suppressing agent as well as a blocking agent. The purpose of this study was to examine EA effects on DMBA tumor initiation and post-initiation promotion/progression in an alternative multiorgan model. Rainbow trout, a useful comparative species for chemoprevention studies (17, 18) , develop liver carcinoma, kidney nephroblastoma, stomach adenopapilloma, and/or swim-bladder adenopapilloma, depending on the DMBA exposure protocol employed (19, this study). This model was used to examine dietary EA influence on the initiation and postinitiation phases of DMBA tumorigenesis in trout liver, stomach and swim-bladder. OR, as previously described (17) . All animals were treated according to guidelines from NLH and protocols approved by the Institutional Animal Care and Use Committee at Oregon State University. Trout fry for tumor studies were reared on Oregon Test Diet (OTD) (17) for 9 weeks to an average weight of 0.75 g. Trout were initiated with DMBA either by water-bath gill uptake (experiments 1 and 2) or by dietary exposure (experiment 3) protocols. For the former, single or duplicate lots of 100 trout fry were exposed in the dark for a specified time to a continuously aerated DMBA suspension in a static water bath containing 1% DMSO as solvent. Negative controls were treated with DMSO alone. After initiation, fish were transferred to 3-foot diameter fiberglass tanks supplied with 13°C well water at a flow rate of 3.5 gallons/min.
To examine EA blocking of bath initiation in experiments 1 and 2, single or duplicate lots of 100 fish each were fed OTD with or without added EA for 1 or 3 weeks before and 3 days after DMBA bath exposure. Control OTD diet was then fed until termination of the experiment after 42 weeks. In the post-initiation studies, fish were fed diets containing 0, 100, 250 (experiment 1) or 0, 1000 or 2000 (experiment 1) p.p.m. EA in OTD for 19 weeks (experiment 1) or 17 weeks (experiment 2), starting 1 week after DMBA bath treatment. Experiment 3 examined blocking activity of EA fed concurrently with DMBA in a dietary initiation protocol. Duplicate groups of 100 animals each were fed OTD containing 750 p.p.m. DMBA and 0 or 1000 p.p.m. EA. These diets were prepared by incorporating DMBA into the oil and EA as a fine suspension in the water component of the OTD formulation, respectively. DMBA diets were fed once a day at 2 g dry diet per 100 g mean fish body weight for 7 weeks, followed by OTD alone for 35 additional weeks.
Pathology and statistical analyses
Experiments were terminated 42 weeks after commencing DMBA exposure. Where available, 100 fish from each treatment lot were killed with an overdose of tricaine methanesulfonate solution. Body and liver weights were individually recorded, and liver, stomach, swim-bladder and kidney were inspected for visual tumors. All livers, and all other organs with visual tumors, were collected and fixed.in Bouin's solution for further analysis (100% of tumors s: 1 mm diameter in stomach, bladder, and kidney are surface oriented in trout and readily detected by simple inspection). Tumors in fixed organs were counted and measured in size, and further processed for histopathological diagnosis according to previously described procedures and criteria (19, 20) .
Statistical analyses of treatment effects on tumor incidence were done using logistic regression models calculated with the GENMOD procedure of SAS for Windows, Version 6.10 (SAS Institute Inc., Cary, NQ. The binomial distribution was used as the probability distribution of the response and the logit function used as the link function. Modeling was done under the assumption of no tank effect and pooling across duplicate tanks, since there was no indication of consistent differences between duplicate tanks. The following model was used: \o%it(P) = a + P|f] + ... + pVr/M> w ' m Ptumor response, // = treatment variables, a and P = estimates for the response of different treatment groups. The model used to estimate the influence of body weight on final tumor incidence was: logit(p) = a + (Jl • (1 + .... + p7-l • ti -1 + y • wt, with wt = final body weight and y the estimated response per g weight. Possible interactions between treatment and weight were tested to ensure that the data fit a parallel linear logistic model. (It is important to stress that we have modeled the entire data set, and have asked if the results are consistent with a series of parallel curves. We do not exclude the possibility that regression of data from any individual treatment group would provide a different slope and intercept.) The likelihood ratio statistics generated from these models estimate the probability of differences among treatment groups as a test of common intercepts, based on the chi 2 -distribution. Comparisons between individual treatment groups within one model were calculated using the Contrast statement of the GENMOD procedure, generating statistics based on the asymptotic chi 2 -distribution. Treatment effects on tumor multiplicity (number of tumors per tumor bearing animal) were analyzed using the non-parametric Wilcoxon test, calculated with the NPAR1WAY procedure of the SAS software. ANOVA procedures were used to test treatment effects on average body weight and liver index, which is defined as the ratio of liver weight to body weight.
Results

Post-initiation EA effects on tumor response
Two experiments were carried out to examine the effects of chronic post-initiation EA treatment on tumor development (Table I) . EA was found to suppress significantly stomach tumor incidence (P < 0.001) in all dose groups in experiments 1 and 2, and to suppress swim-bladder incidence at 1000 and 2404 2000 p.p.m. (P < 0.05) in experiment 1. Figure 1 depicts the relationship between decreasing stomach tumor incidence and increasing lifetime EA amount received in the two independent studies. The inhibitory effect of EA in stomach was accompanied by a change in tumor size distribution from 1.0 ± 0.5 mm towards smaller, 0.5 ± 0.2 mm tumor diameter (P < 0.001) in experiment 1. These small tumors comprised 83% and 95% of the total tumors in the 1000 p.p.m. and 2000 p.p.m. groups, respectively, compared with 29% in the control animals. Average stomach tumor multiplicity was also significantly reduced in all EA treatment groups in the two studies (P < 0.001, Table I ).
Swim-bladder papilloma incidence also decreased to 41% (1000 p.p.m. EA) and to 35% (2000 p.p.m. EA) of the control value in study 1, but no effect was seen at the lower doses in study 2 (Table I ). In contrast to the suppressive effect on stomach and swim-bladder incidence, liver tumor incidence was significantly increased by EA doses of 250 p.p.m. and higher (Table I ). This occurred even though body weight was decreased in these groups (Table I ). This may reflect promotion of hepatocarcinogenesis due to the liver toxicity evident at these higher EA doses, but could also include more subtle post-initiation mechanisms supporting a shift in tumor burden within the multi-organ model. There was no indication that high-dose EA enhancement of liver response altered the proportion of hepatic tumor phenotypes.
Our first tumor study, experiment 1, involved chronic exposure to 1000 and 2000 p.p.m. EA, which were selected to be comparable to EA doses used in rodent studies. Although short-term exposures to these levels have shown no adverse effect in trout, prolonged treatment during the tumor study led to the unexpected development of diet refusal and growth inhibition in the treated animals starting after 8-10 weeks, with some mortality (11/100) in the 2000 p.p.m. dose group (Table I , experiment 1). The growth inhibition effect led to a considerably reduced average body weight of 40-50% of the corresponding negative control group at termination of the experiment. Fish treated with high dose EA were also noticeably darker in color than animals from control groups, and the liver tissue of these fish was brittle and pale. The total exposure to EA was consequently limited to 17 weeks for the 1000 and 2000 p.p.m. groups. At the lower doses used in experiment 2, 100 p.p.m. EA produced no growth depression, whereas the 250 p.p.m. treatment appeared close to the maximum tolerated dose (MTD), with a 14% lower mean growth rate compared to the control group (Table I) . EA fed chronically at 2000 p.p.m. to sham-treated animals produced similar growth depression, but did not produce tumors in any organ (Table I , experiment 1).
Influence of growth on tumor response
Tumor studies involving treatment-related growth reductions greater than 10% are usually not further evaluated because of the uncertain contribution of systemic or organ-specific toxicities. However, because of the number of animals involved, experiment 1 provided an opportunity to examine the possible quantitative inter-relationship between reduced growth and tumor response and to determine if the otherwise flawed result may have predictive value. Therefore, rather than discard the study, we analyzed this inter-relationship in two ways. Figure 2 A shows a simple comparison of stomach tumor incidence among groups of animals stratified according to growth rate classes, for control and EA-treated animals from Initiation in static water bath containing 1% DMSO, negative controls were sham-treated with 1% DMSO only. c Percent ratio between liver weight and body weight. ''Tumor number per tumor bearing animal. Means ± SD are shown for informative purpose only. Non-parametric rank tests were used for statistical analysis. C EA incorporated into OTD diet, pre-initiation: fed 1 week prior to initiation and 3 days after initiation, post-initiation: fed for 17 weeks. f EA incorporated into OTD diet, pre-initiation: fed 3 weeks prior to initiation and 3 days after initiation, post-initiation: fed for 19 weeks.
•Initiation by dietary exposure for 7 weeks.
•"Only 83 of 100 surviving fish were sampled for tumor incidence.
Different from positive control groups with P < 0.05, 0.01; P < 0.001, repectively. experiment 1. First, as routinely observed for liver tumors in this model (unpublished results), stomach tumor response was positively related to total growth, such that individuals within the most rapidly growing category had the highest probability of tumor development. Second, by simple inspection it is evident that animals receiving EA treatment experienced a similar degree of reduced tumor response compared to controls, in every weight class examined. Though this approach is qualitative, the results strongly suggest that there are mechanisms of EA suppression independent of any EA effects on growth rate. Subsequently, a more exacting analysis was carried out by incorporating fish weight as an independent variable into a logistic regression model. Plots of mean body weight of each class versus logit tumor incidence in that class were modeled as a set of linear curves, parallel (see Materials and methods) in slope ( Figure 2B and C). The parallel relationship simply means that EA treatment did not significantly perturb the relationship between growth rate and tumor outcome. In this model, slope quantifies the influence of growth rate on tumor response within a given treatment group, whereas vertical offset between curves can estimate treatment effects independent of body weight. The final modeling verified an overall significant effect of body weight on tumor incidence in stomach (P < 0.001) ( Figure  2B and C) and swim-bladder (P < 0.05, data not shown) in both studies. There was also evidence (data not shown) of an effect of growth rate on liver tumor incidence (P < 0.001) in study 2 (low EA ) but not in study 1 (P = 0.087), probably due to the low number of liver tumors in this study. In the analysis, it should be noted that incidences of 100% and 0%, though informative, cannot be adequately plotted on a logit scale. Several points emerge from this analysis. First, the suggestion by Figure 2A that total growth strongly influences stomach tumor development in the trout model is confirmed (i.e. the slopes of the regression lines are not zero, P < 0.001). For example, DMBA initiated fish receiving 100 p.p.m. EA and achieving a total growth to 110 g had a significantly higher stomach tumor incidence (95%) than fish receiving the same DMBA and EA but growing to only 30 g (30% incidence). Second, 100 p.p.m. EA strongly suppressed stomach tumor development in the absence of any effect on mean population growth. Third, the magnitude of parallel departure between the control and EA regression lines quantifies the suppression effect apart from any growth effect due to EA treatment. Were the added suppression at 250 p.p.m. EA, for example, due only to growth-related toxicity, the data sets for 100 and 250 p.p.m. must have described a single line, with the 250 p.p.m. data grouped toward the lower weight end of that line. Clearly this was not the case. To quantify non-growth mechanistic effects, we consider that the DMBA-only control showed 97% incidence at a mean population weight of 66 g/fish. What incidence would be expected at 250 p.p.m. EA, were the EA effect due solely to its reduction in mean weight to 57 g/fish? By calculation from the regression equation, population tumor incidence should have been reduced from only 97 to 95.6%. Hence, the observed reduction down to 39% incidence must be ascribed almost entirely to EA suppression mechanisms other than reduced growth, and the minimal growth depression observed near the EA MTD was mechanistically unimportant. By contrast, the higher doses of EA in study 1 ( Figure 2C ) introduced more serious growth reduction (data points are in fact skewed toward the lower end of the weight distribution scale). Nonetheless, there was still substantial suppression of stomach tumor development independent of growth-related toxicity (i.e. the control and treatment data sets are not colinear). Though data scatter in the DMBA-only group was extensive in this experiment, extrapolations can still approximate the relative contribution of growth effects. The control regression line equation indicates an expected incidence of 92% (actual observed, 88%) at the mean group weight of 88 g/fish. EA-mediated growth suppression to the observed 39 and 42 g/fish for 1000 and 2000 p.p.m. EA, respectively, would be expected from the regression line to have produced incidences of 57 and 60% due to growth reduction alone. Since the observed incidences were 26 and 19%, we can conclude that growth reduction accounted for about half of the suppression effect at high, toxic doses of EA. It also appears that the magnitude of tumor suppression (distance between parallel lines) in Figure 2C was comparable to or less than that shown at lower, non-toxic EA doses in Figure  2B . Our interpretation is that dose-response for EA tumor suppression in this model shows an optimum in the 100-250 p.p.m. range, and that the additional tumor suppression observed at higher EA doses can be ascribed solely to growth reduction and related toxicities. In turn, analysis of experiment 1 data predicted suppression effects unrelated to EA toxicity, and the results of experiment 2 supported this prediction. EA effects on DMBA initiation Three types of experiments were carried out to examine the effect of EA pre-feeding on DMBA tumor initiation (Table I) : EA fed 1 week before and 3 days after DMBA bath exposure (experiment 1); EA fed 3 weeks prior to and 3 days after DMBA bath treatment (experiment 2); and EA co-fed with DMBA for 7 weeks in a dietary initiation protocol (experiment 3). Initiation with DMBA by passive gill uptake induced tumors in liver, stomach and swim-bladder. Stomach adenomas were predominant with an incidence of 88% after initiation with 5 p.p.m. DMBA for 5 h (study 1), or 97% after treatment with 4 p.p.m. DMBA for 16 h (study 2). These treatments also elicited swim-bladder adenopapillomas at 15 and 13.5% incidence and liver tumors at 5 and 6% incidence, respectively. The distribution of liver phenotypes (41 % hepatocellular, 34% mixed hepatocellular/cholangiocellular, 24% cholangiocellular carcinoma and adenoma) was as previously described for DMBA in this model (19). In study 1, a 1-week pre-treatment with 2000 p.p.m. EA resulted in a small but significant reduction in stomach tumor incidence (P < 0.05) and a significantly decreased tumor multiplicity (P < 0.01, Table I ). There was also evidence for inhibition of swim-bladder tumors (P = 0.05). Liver tumor response was low in the positive control, and not significantly affected by the treatment.
Increasing the period of EA pre-feeding to 3 weeks in study 2 eliminated the modest reduction in stomach tumor response seen with only 1 week of pre-feeding (Table I) , even if incidences were adjusted by regression analysis to correct for the greater mean growth rate of the EA pre-treated group. An unexpected result was that the longer period of EA pre-feeding provided a significant, dose-responsive increase in tumor incidence in liver (2.6-fold and 3.5-fold) and in swim-bladder (3.7-fold and 4.6-fold), and aJso increased tumor multiplicity in these organs.
Study 3 is the first reported examination of a dietary DMBA initiation protocol in trout. When fed at 750 p.p.m. for 7 weeks, DMBA elicited predominantly stomach tumors (85% incidence), with very low responses in liver (6%) and swimbladder (1%) in the trout (Table I) . Co-feeding 1000 p.p.m. EA produced a small but significant decrease in stomach tumor incidence (P = 0.048) and multiplicity {P < 0.01). Co-feeding EA did not significantly alter the swim-bladder or liver response.
Discussion '
Ellagic acid tumor suppression EA occurs in the diet as a component of hydrolyzable ellagitannins (21). EA and several other dietary phenolics have been considered blocking agents (12, 13, 22) , because of their frequently observed anti-carcinogenic activity when administered during the initiation phase in rodent models. The studies presented here show that EA also can act as an inhibitor of DMBA-initiated stomach and swim-bladder carcinogenesis in the rainbow trout model. In this model EA was relatively ineffective as a blocking agent, but provided substantial protection in the post-initiation (promotion/progression) phase of carcinogenesis in stomach. These studies support recently published evidence from rats (15, 16) that dietary EA can suppress tumor development, in this case in a complete carcinogenesis protocol without exogenous promoter.
The mechanisms behind this effect, however, are not clear. EA has shown anti-oxidant and ami-promoting activity against TPA in DMBA-initiated mouse skin when given topically (14) and caused a sustained decrease of cellular proliferation in tongue epithelium after 4-nitroquinoline-1 -oxide initiation in rats (21). Recent reports demonstrate inhibitory activity of ellagitannins on protein kinases including protein kinase C (23, 24) and the inhibition of DNA-topoisomerases by EA (25) . The influence of EA on such signal transduction/cell proliferation enzymes could be the basis of its anti-proliferative and tumor suppressing activity, but we have no evidence for this in trout.
Higher doses of EA given chronically to trout caused toxicity and reduced growth after prolonged treatment (>8-10 weeks), with an MTD in this model near 250 p.p.m. This MTD is 50 to 100 times lower than the 10 000 p.p.m. MTD reported for male F344 rats (26) . EA reportedly shows limited absorption and biodistribution in rodents. For example, high-dose EA given by gavage produced only 70 p.p.m. EA in mouse lung tissue and a 10-fold lower level in liver (4) . EA biodistribution has not been assessed in trout, a model in which the stomach is the major absorption organ. However, the substantial tumor modulating effects of dietary EA in trout organs outside the gastrointestinal tract might be taken to indicate greater EA bioavailability (and consequent hepatotoxicity) in this model. An alternative hypothesis is that EA-mediated tumor modulation in liver and swim-bladder may be an indirect effect, in which dietary EA reduces the bioavailability of micronutrients inhibitory to tumor development in these organs in trout. It is noteworthy that EA did not suppress trout liver tumor response, nor have we ever observed liver cancer suppression among the many chemoprevention studies we have conducted in this model. There is also remarkably little evidence for liver tumor suppression in rodent models (27) (28) (29) , which may suggest that chemoprevention of liver cancer will require focus on blocking agents and not suppressing agents.
Apportionment of growth and non-growth mechanisms
Experiment 2 demonstrated substantial stomach tumor suppression at EA doses inducing little (250 p.p.m.) or no (100 p.p.m.) observable diet refusal or growth deficit, and no evident liver toxicity. It could be argued, however, that tumor suppression at the higher, toxic EA doses in our first experiment may have been largely or entirely a result of calorie deficit and poor growth attendant with diet refusal. Dietary and caloric restriction have long been known to influence tumor development in other experimental animals (30,31). We have described an approach for separating growth-related from non-growthrelated mechanisms of tumor modulation. The parallel logistic regression approach clearly demonstrated not only a highly significant association between the probability of developing stomach and swim-bladder tumors and the growth rate of the individual, but also revealed an additional component of EA suppression in these organs separate from any EA effects on mean population growth rate. The results showed that the observed reduction in tumor incidence in stomach and swimbladder at high EA was only in part explained by growth-related toxicities, and that additional EA suppression mechanisms must also be operating. Whether these are the same mechanisms as those operating at low EA dose is not known. We have used analogous regression models previously to quantify the effects of other modulators over a range of carcinogen and modulator doses (32, 33) .
The body weight analysis shown here illustrates a practical advantage of the trout; the larger number of animals afforded in a typical tumor study can yield interpretations that may be unavailable from typical rodent study designs. Experiment 1 was not designed with the knowledge that serious treatmentrelated toxicity should occur, nor would this be done in the usual rodent tumor study. However, when this did occur inadvertently, apportionment analysis of the resulting data was useful in correctly predicting the existence of modulator mechanisms separate from growth-related toxicities. Ellagic acid as a blocking agent Inhibition of initiation by dietary EA has been reported for 4-(methylnitrosamino)-l-(3-pyridyl)-1-butanone-induced lung carcinogenesis in mice (4), TV-nitrosobenzylmethylamineinduced esophageal carcinogenesis in rats (5), DMBA-induced mammary carcinogenesis in rats (12) and in a multi-organ rat model against lung and small intestinal tumors (15) . In trout, the modulating activity of EA during the initiation phase varied with DMBA exposure protocol, EA dose, EA treatment period, and target organ examined. Thus, extending EA pre-treatment from 1 week to 3 weeks seemed to impair its modest blocking effect on stomach and swim-bladder carcinogenesis, and instead caused a dose-responsive enhancement of liver and swim-bladder tumors in fish initiated by the single-dose DMBA treatment. The mechanisms underlying these varying effects are not clear, but may reflect dose and time-dependent shifts in carcinogen biodistribution or metabolism. Organ-specific EA modulating activity has also been reported in the rat. EA fed at the MTD of 10 000 p.p.m. during initiation was found strongly to increase pre-neoplastic foci in liver, but to inhibit small intestinal tumors and lung tumor multiplicity (15) .
Dietary DMBA administration induced predominantly stomach tumors, with little response in liver or swim-bladder. With this initiation protocol, even 7 weeks of high-dose EA co-treatment did not significantly alter liver or swim-bladder tumor response, which emphasizes the protocol dependency of EA tumor modulating activity during initiation. The efficacy of EA against DMBA in rodents also seems to vary among protocols, including those in which EA fails to produce significant modulation (9) .
In summary, the studies reported here demonstrate that EA can display potent anticarcinogenic activity against a model polycyclic aromatic compound in a multi-organ trout model, and that suppression of stomach tumor development in this model is achievable at EA doses far lower than those required for efficacy in rodents. However, some treatment protocols at higher EA doses lead to enhanced tumor development in trout liver and swim-bladder, similar to EA organ-specific enhancing effects recently reported in a rodent multi-organ model (15) . High-dose EA enhancing effects in the trout were observed for short-term EA treatment protocols that did not produce observable toxicity, as well as chronic exposures producing substantial growth suppression.
